ReviewFrontiers in immunology2019

The Complement Receptors C3aR and C5aR Are a New Class of Immune Checkpoint Receptor in Cancer Immunotherapy.

Yu Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.